公告称，公司已于2021年11月开始KN035(恩沃利单抗注射液)的商业化。KN046预计将于2024年根据一线鳞状NSCLC的OS最终分析结果确定是否提交NDA及KN026预计将于2025年提交NDA。值得注意的是，今年5月份公司曾宣布，KN046-303试验总生存期结果未达预设终点。CSPC Pharmaceutical Group-B (09966) is now down more than 5%, as of press time, down 5.56%, at HKD 2.38, with a turnover of 4.2985 million HKD.
According to the Smart Finance app, CSPC Pharmaceutical Group-B (09966) is now down more than 5%, as of press time, down 5.56%, at HKD 2.38, with a turnover of 4.2985 million HKD.
On the news front, CSPC Pharmaceutical Group recently announced its interim performance, with revenue of approximately 1.74 billion yuan, a year-on-year growth of 27.18%; research and development expenses of approximately 1.95 billion yuan, basically flat compared to the same period last year; a loss of 448.96 million yuan during the period, an increase of 12.63% year-on-year; a loss per share of 0.05 yuan. The company also announced its plan to repurchase up to 50 million HKD worth of shares.
In the announcement, the company stated that the commercialization of KN035 (Envolidarptin injection) began in November 2021. KN046 is expected to submit an NDA based on the final analysis results of OS in one-line squamous NSCLC in 2024, and KN026 is expected to submit an NDA in 2025. It is worth noting that in May of this year, the company announced that the KN046-303 trial did not meet the pre-specified endpoint for overall survival.
